CCIA
MDGL icon

Campbell & Co Investment Adviser’s Madrigal Pharmaceuticals MDGL Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-718
Closed -$222K – 1209
2024
Q4 		$222K Buy
+718
New +$202K 0.02% 941
2023
Q4 		– Sell
-6,571
Closed -$960K – 1238
2023
Q3 		$960K Buy
+6,571
New +$1.24M 0.11% 282
2023
Q1 		– Sell
-1,438
Closed -$417K – 939
2022
Q4 		$417K Buy
+1,438
New +$141K 0.1% 397
2022
Q2 		– Sell
-13,196
Closed -$1.29M – 820
2022
Q1 		$1.29M Buy
+13,196
New +$1.11M 0.35% 42
2021
Q4 		– Sell
-5,000
Closed -$399K – 734
2021
Q3 		$399K Buy
+5,000
New +$432K 0.13% 284

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Campbell & Co Investment Adviser's MDGL Position: Q1 2025 in Review

Campbell & Co Investment Adviser sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 718 shares — an estimated $222K sold.

Campbell & Co Investment Adviser first reported a position in MDGL in Q3 2021 and held it in 5 quarters. The position peaked at $1.29M in Q1 2022. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Campbell & Co Investment Adviser reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 718 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $222K.
  • Campbell & Co Investment Adviser first reported a position in Madrigal Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • Campbell & Co Investment Adviser's Madrigal Pharmaceuticals position peaked at $1.29M in Q1 2022.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2025, filed 14 May 2025.